AOD9604

Peptide fragment of human growth hormone

Chemical structure of AOD9604

AOD9604 is a peptide fragment derived from the human growth hormone (hGH). It is specifically a modified form of the C-terminal fragment of hGH, consisting of amino acids 177-191. This peptide has been studied for its potential effects on lipolysis and obesity management.

Structure and Function

AOD9604 is a synthetic analog of the human growth hormone fragment 177-191. It is designed to mimic the lipolytic (fat-reducing) activity of hGH without the adverse effects associated with the full hormone. The peptide is composed of 15 amino acids and has been modified to enhance its stability and bioavailability.

The primary function of AOD9604 is to stimulate the breakdown of fat and inhibit the formation of new fat in the body. It achieves this by mimicking the activity of the natural hGH fragment, which is known to regulate fat metabolism.

Mechanism of Action

AOD9604 works by activating the same pathways as the natural growth hormone fragment. It binds to specific receptors on the surface of fat cells, triggering a cascade of biochemical reactions that lead to the breakdown of stored fat (lipolysis) and the prevention of new fat accumulation. Unlike the full growth hormone, AOD9604 does not appear to affect insulin levels or glucose metabolism, making it a potentially safer option for weight management.

Clinical Applications

AOD9604 has been investigated for its potential use in treating obesity and related metabolic disorders. Clinical trials have explored its efficacy in reducing body fat and improving metabolic parameters in overweight and obese individuals. However, as of now, AOD9604 is not approved by major regulatory bodies such as the Food and Drug Administration (FDA) for medical use.

Safety and Side Effects

Studies on AOD9604 have generally shown it to be well-tolerated, with a low incidence of side effects. Unlike full-length hGH, AOD9604 does not appear to cause hyperglycemia, carpal tunnel syndrome, or other common side effects associated with growth hormone therapy. However, more extensive research is needed to fully understand its long-term safety profile.

Regulatory Status

AOD9604 is not approved for therapeutic use by the FDA or other major health authorities. It is often marketed as a research chemical or dietary supplement, but its sale and use are subject to regulatory restrictions in many countries.

Related Pages

• Human growth hormone
• Lipolysis
• Obesity
• Peptide therapy